
Novo Nordisk has summoned Orbicular Pharmaceutical Technologies before a court in Delaware in the US to block the launch of a generic copy of its obesity drug, Saxenda, Bloomberg News reports.
In the case, Novo Nordisk claims that a generic copy of Saxenda would violate 18 of Novo’s patents on the injectable obesity drug.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app